CoChat

A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax Plus Docetaxel in Patients with Advanced Solid Tumors

Open access
Puglisi, Martina, Molife, L Rhoda, de Jonge, Maja JA, Khan, Khurum H, Doorn, Leni van, Forster, Martin D, Blanco, Montserrat, Gutierrez, Martin, Franklin, Catherine, Busman, Todd, Yang, Jianning, Eskens, Ferry ALM · 2021 · Future Oncology
Cited by 32

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aim: This Phase I study investigated safety of navitoclax and docetaxel in patients (n = 41) with advanced solid tumors. Patients & methods: Two navitoclax plus docetaxel dosing schedules (21 and 28 days) were evaluated. Maximum tolerated dose, dose-limiting toxicities and preliminary antitumor activity were assessed. Results: Ten (24%) patients experienced dose-limiting toxicities; dose-escalation cohorts: n = 7 (21-day schedule: n = 5; 28-day schedule: n = 2) and 21-day expanded safety cohort: n = 3. Navitoclax 150-mg days 1–5 every 21 days with docetaxel 75 mg/m2 day 1 was the maximum tolerated dose and optimal schedule. Adverse events included thrombocytopenia (63%), fatigue (61%), nausea (59%) and neutropenia (51%). Four confirmed partial responses occurred. Conclusion: Navitoclax 150-mg orally once/day was safely administered with docetaxel. Myelosuppression limited dose escalation; antitumor activity was observed. Clinical trial registration: NCT00888108 (ClinicalTrials.gov)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon-2021-0140

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 32

Metadata

Authors
Puglisi, M., Molife, L. R., de Jonge, M. J., Khan, K. H., Doorn, L. V., Forster, M. D., Blanco, M., Gutierrez, M., Franklin, C., Busman, T., Yang, J., & Eskens, F. A.
Venue
Future Oncology
Published
2021-04-14
Volume
17
Issue
21
Pages
2747-2758
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W3156996079
Cited by
32
References
8
FWCI
1.47
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax Plus Docetaxel in Patients with Advanced Solid Tumors. https://app.cochat.ai/papers/10.2217/fon-2021-0140
The paper
Puglisi, M., Molife, L. R., de Jonge, M. J., Khan, K. H., Doorn, L. V., Forster, M. D., Blanco, M., Gutierrez, M., Franklin, C., Busman, T., Yang, J., & Eskens, F. A. (2021). A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax Plus Docetaxel in Patients with Advanced Solid Tumors. Future Oncology. https://doi.org/10.2217/fon-2021-0140

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.